Pyxis Oncology, Inc. has initiated a Phase 1/2 combination trial of its product PYX-201 with Merck's KEYTRUDA, targeting various advanced solid tumors. The company also expands its Phase 1 monotherapy trial to include patients with recurrent/metastatic head and neck squamous cell carcinoma.

Pyxis Oncology is transforming the lives of patients with cancer by advancing our differentiated portfolio of biologics that specifically target tumor cells and overcome immune suppression. We believe that antibody-drug conjugates (ADCs) and immunotherapies have the potential to address difficult-to-treat cancers and improve patient outcomes.



Pyxis Oncology Launches Phase 1/2 Trials for PYX-201 in Combination with KEYTRUDA to Treat Advanced Solid Tumors.

Product Description

Company Information

Product Launch Insights

Related People

Pyxis Oncology Launches Phase 1/2 Trials for PYX-201 in Combination with KEYTRUDA to Treat Advanced Solid Tumors.

Product Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Product Launch Insights

Related People

Company Information